Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Metampicillin is a β-lactam antibiotic of the penicillin class, prepared by reacting ampicillin with formaldehyde. It acts as a prodrug, rapidly hydrolyzed in acidic environments such as the stomach to release ampicillin. Metampicillin exerts its antibacterial effect by inhibiting bacterial cell wall synthesis through binding and inactivation of penicillin-binding proteins (PBPs), which are essential for cross-linking peptidoglycan chains and maintaining cell wall integrity. This leads to weakening of the bacterial cell wall and eventual lysis. Metampicillin has a similar antibacterial spectrum to ampicillin but is reported to be absorbed more efficiently when administered orally or parenterally, resulting in higher blood and biliary concentrations compared to ampicillin alone. It is particularly effective for treating biliary tract infections due to its high accumulation in bile[1][2][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on metampicillin.